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Abstract
The present study investigated how repeated administration of aripiprazole (a novel antipsychotic drug) alters its behavioral effects in two behavioral tests of antipsychotic activity and whether this alteration is correlated with an increase in dopamine D2 receptor function. Male adult
Sprague-Dawley rats were first repeatedly tested with aripiprazole (3, 10 and 30 mg/kg, subcutaneously (sc)) or vehicle in a conditioned avoidance response (CAR) test or a phencyclidine (PCP) (3.20 mg/kg, sc)-induced hyperlocomotion test daily for five consecutive days. After 2–3 days
of drug-free retraining or resting, all rats were then challenged with aripiprazole (1.5 or 3.0 mg/kg, sc). Repeated administration of aripiprazole
progressively increased its inhibition of avoidance responding and PCP-induced hyperlocomotion. More importantly, rats previously treated with
aripiprazole showed significantly lower avoidance response and lower PCP-induced hyperlocomotion than those previously treated with vehicle
in the challenge tests. An increased sensitivity to quinpirole (a selective D2/3 agonist) in prior aripiprazole-treated rats was also found in the quinpirole-induced hyperlocomotion test, suggesting an enhanced D2/3-mediated function. These findings suggest that aripiprazole, despite its distinct receptor mechanisms of action, induces a sensitization effect similar to those induced by other antipsychotic drugs and this effect may be
partially mediated by brain plasticity involving D2/3 receptor systems.
Keywords: Aripiprazole, conditioned avoidance response, phencyclidine, quinpirole, sensitization, tolerance

Introduction

induced sensitization has been linked to the gradual development of some extrapyramidal motor side effects (Turrone et al.,
2005), increased dopamine supersensitivity (Samaha et al., 2007),
and the progressive improvement of psychosis (Agid et al., 2003).
One important issue in the field of antipsychotic sensitization and tolerance is to identify the critical factors that determine the specific patterns of the long-term effects of chronic antipsychotic drug treatment. Among many potential factors, two
seem prominent. One is the drug administration schedule (e.g.
intermittent vs continuous), as many studies have shown that
continuous or frequent drug administration produces some degree of tolerance, while more intermittent injections can result
in sensitization (Remington and Kapur, 2010). The second factor
is the specific drug type (e.g. clozapine vs olanzapine). In recent
years, we have shown that under the same intermittent drug administration schedule, haloperidol, olanzapine, risperidone, and
asenapine all produce a sensitization-like effect in their suppres-

Patients with schizophrenia take antipsychotic drugs chronically
to manage their psychotic symptoms. It is thus of great importance to understand the effects of long-term antipsychotic treatment on brain functions and related psychological functions to
better understand the therapeutic and side effects of antipsychotic medications. Many clinical and preclinical studies have
reported that chronic administration of antipsychotic drugs often cause either an augmentation or decrease of some of the
acute effects of a drug, termed antipsychotic sensitization and
tolerance, respectively (Remington and Kapur, 2010; Samaha
et al., 2007, 2008; Zhang and Li, 2012). These two phenomena
can manifest at multiple levels, including neurotransmitter release, changes in neuroreceptor levels, receptor-mediated second messenger activities, cell electrophysiology, and behaviors,
and which can be clinically relevant. For example, haloperidol390
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sion of the conditioned avoidance response (CAR) and phencyclidine (PCP)-induced hyperlocomotion (two independent behavioral effects predictive of antipsychotic activity) (Feng et al.,
2013; Li et al., 2012; Mead and Li, 2010; Qiao et al., 2013; Qin et
al., 2013; Swalve and Li, 2012; Zhang and Li, 2012). However, clozapine produces a tolerance-like effect in these tests (Feng et al.,
2013; Li et al., 2010; Qiao et al., 2013). These findings suggest
that antipsychotic sensitization and tolerance is also a drug specific phenomenon, in addition to its schedule-dependent feature.
The present study was intended to further examine the drugspecificity issue of antipsychotic sensitization and tolerance by
determining what type of repeated effect (sensitization or tolerance) that aripiprazole would induce and whether such an effect is associated with changes in dopamine D2 receptor system
(Gao and Li, 2013). We are interested in aripiprazole because it
is a new antipsychotic drug with a unique pharmacological profile distinct from the conventional and atypical antipsychotics
(Mamo et al., 2007). It is a partial 5-hydroxytryptamine 1A (5HT1A) receptor agonist and 5-HT2A receptor antagonist, but unlike other antipsychotics, which are potent D2 receptor antagonists, aripiprazole has partial agonist activity on these receptors
(Bortolozzi et al., 2007; Burris et al., 2002; Jordan et al., 2002).
Its long-term effects in animal behavioral tests of antipsychotic
drugs have never been assessed and the behavioral pattern (i.e.
sensitization or tolerance) it would induce is not known.
In this study, we employed a paradigm that has been validated in our previous CAR and PCP-induced hyperlocomotion
work. This paradigm consists of two phases of drug effect assessment: an induction phase and an expression phase (Feng
et al., 2013; Li et al., 2010, 2012; Mead and Li, 2010; Qiao et al.,
2014; Shu et al., 2014; Swalve and Li, 2012, Zhang and Li, 2012).
In the induction phase, rats are repeatedly treated with an antipsychotic drug or vehicle for a certain number of days (e.g. five
or seven days), and the drug’s suppressive effect on avoidance
response and PCP-induced hyperlocomotion is recorded daily.
In the expression phase, all rats are given a challenge dose of
the drug and tested for avoidance response and PCP-induced
hyperlocomotion. Two measures are taken to index the potential sensitization or tolerance effect of the drug. The first index of
antipsychotic sensitization/tolerance is obtained from the induction phase and is revealed through a within-subjects comparison,
in which the behavioral effect of a drug treatment is stronger/
weaker on the last treatment day than the first day (i.e. a comparison between days 1 and 5). The second index is obtained
from the expression phase and is provided by a between-subjects comparison, in which the behavioral response of drug-pretreated animals to a challenge dose of an antipsychotic drug is
compared to the response of vehicle- pretreated control animals.
Here, antipsychotic sensitization/ tolerance is demonstrated by
increased/decreased sensitivity to the drug challenge in drugpretreated animals relative to those pretreated with vehicle. In
addition, because our recent work suggests that risperidone-induced sensitization in the conditioned avoidance response test
is correlated with an increase in D2-mediated motor activity, as
assessed in the quinipirole (a dopamine D2/3 receptor agonist)induced hyperlocomotion test (Gao and Li, 2013), we also examined whether repeated aripiprazole would also cause a similar change in D2 receptor function.
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Materials and method
Animals

Adult male Sprague-Dawley rats (226–250 g upon arrival,
Charles River, Portage, Michigan, USA) were housed two per
cage, in transparent polycarbonate cages (48.3×26.7×20.3 cm,
or 39.5×34.6×21.3 cm) under 12-hour light/dark conditions (light
on between 06:00–18:00). Room temperature was maintained at
22±1°C with a relative humidity of 45–60%. Food and water was
available ad libitum. Rats were allowed at least five days of habituation to the animal facility before being used in experiments. All
behavioral tests took place between 09:00–17:00 in the light cycle. All experimental treatments and procedures were approved
by the Institutional Animal Care and Use Committee at the University of Nebraska-Lincoln.

Drugs and choice of doses

Aripiprazole (gift from the National Institute of Mental Health
drug supply program) was dissolved in a mixed double-distilled
water solution containing 30% (v/v) dimethylformamide and 2%
(v/v) glacial acetic acid. Doses of aripiprazole (3, 10 and 30 mg/
kg) were determined based on our previous studies (Li et al., 2005)
and reports in the literature (Carli et al., 2011; Cosi et al., 2006; Li
et al., 2004; Natesan et al., 2006). These doses of aripiprazole give
rise to 71%, 85%, and 84% D2 occupancies, respectively, at one
hour post injection (Natesan et al., 2006), but do not cause catalepsy (Hirose et al., 2004). The dose of PCP (3.20 mg/kg) was chosen based on our previous work (Shu et al., 2014; Sun et al., 2009,
2010; Zhang and Li, 2012; Zhao et al., 2012). This dose of PCP is
shown to induce a robust hyperlocomotion effect without causing severe stereotypy (Gleason and Shannon, 1997; Kalinichev et
al., 2008). The chosen quinpirole dose (1.0 mg/kg) targets postsynaptic D2/3 receptors and causes an increase in motor activity
(Koller et al., 1987; Luque-Rojas et al., 2013; Nakamura et al., 1994;
Prosser et al., 1989). This dose of quinpirole was chosen based on
the similar studies from our laboratory (Gao and Li, 2013; Qiao et
al., 2014). Quinpirole was dissolved in 0.9% saline. All drugs were
administrated subcutaneously (sc) at 1.0 ml/kg.

Apparatus

Two-way avoidance conditioning apparatus. Eight identical twoway shuttle boxes custom designed and manufactured by Med
Associates (St. Albans, Vermont, USA) were used. Each box was
housed in a ventilated, sound-insulated isolation cubicle (96.52
cm W×35.56 cm D×63.5 cm H). Each box was 64 cm long, 30
cm high (from grid floor), and 24 cm wide, and was divided
into two equal-sized compartments by a partition with an arch
style doorway (15 cm high×9 cm wide at base). A barrier (4 cm
high) was placed between the two compartments, so the rats
had to jump from one compartment to the other. The grid floor
consisted of 40 stainless-steel rods with a diameter of 0.48 cm,
spaced 1.6 cm apart center to center, through which a scrambled footshock (unconditioned stimulus, US, 0.8 mA, maximum
duration: 5 s) was delivered by a constant current shock generator (Model ENV-410B) and scrambler (Model ENV-412). The rat
location and crossings between compartments were monitored
by a set of 16 photobeams (ENV-256-8P) affixed at the bottom
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Figure 1. A schematic illustration of the experimental procedure and groups in experiment 1 (conditioned avoidance response (CAR) model) and
experiment 2 (phencyclidine (PCP) model). ARI: aripiprazole; CS: conditioned stimulus; QUI: quinpirole; US: unconditioned stimulus; VEH: vehicle.

of the box (3.5 cm above the grid floor). Illumination was provided by two houselights mounted at the top of each compartment. The conditioned stimulus (CS), i.e. 76 dB white noise) was
produced by a speaker (ENV 224 AMX) mounted on the ceiling
of the cubicle, centered above the shuttle box. Background noise
(approximately 74 dB) was provided by a ventilation fan affixed
at the top corner of each isolation cubicle. All training and testing procedures were controlled by Med Associates programs
running on a computer.
Locomotor activity monitoring apparatus. The motor activity testing apparatus is described in detail before (Feng et al., 2013;
Sun et al., 2009; Zhao and Li, 2012). Sixteen activity boxes were
housed in a quiet room. The boxes were 48.3×26.7×20.3 cm
transparent polycarbonate cages, which were similar to the home
cages but were each equipped with a row of six photocell beams
(7.8 cm between two adjacent photobeams) placed 3.2 cm above
the floor of the cage. A computer with recording software (Aero
Apparatus Sixbeam Locomotor System v1.4, Toronto, Canada)
was used to detect the disruption of the photocell beams and
recorded the number of beam breaks. All experiments were run
during the light cycle.

Experiment 1: Effect of repeated aripiprazole
treatment on avoidance responding

This experiment examined whether repeated aripiprazole treatment induces a sensitization or tolerance effect in the CAR
model and whether this sensitization or tolerance is accompa-

nied by dopamine receptor changes. The experiment was comprised of the following three phases: Phase 1: avoidance training
and five days of repeated aripiprazole testing; phase 2: aripiprazole challenge test; and phase 3: quinpirole-induced hyperlocomotion test. Figure 1 summarizes the entire experimental procedure and groups at different phases of the experiment.
Phase 1: Avoidance training in CAR and five days of repeated aripiprazole testing. Forty rats were first habituated to the CAR
boxes for two days (30 min/day). They were then trained to make
avoidance responding for 10 days/sessions. Each session consisted of 30 trials. Every trial started by presenting a white noise
(CS) for 10 s, followed by a continuous scrambled foot shock (0.8
mA, US, maximum duration=5 s) on the grid floor. If a subject
moved from one compartment into the other within the 10 s of
CS presentation, it avoided the shock and this shuttling response
was recorded as avoidance. If the rat remained in the same compartment for more than 10 s and made a crossing upon receiving
the footshock, this response was recorded as escape. If the rat
did not respond during the entire 5 s presentation of the shock,
the trial was terminated and the intertrial intervals started. The
total number of avoidance responses was recorded for each session. Intertrial intervals varied randomly between 30 and 60 s.
At the end of the training session, 36 rats reached the training criterion (≥70% avoidance in each of the last two sessions).
They were first matched on avoidance performance on the last
training day (i.e. pre-drug) to create blocks of rats (n=4 rats/
block) that were approximately equal in performance. Within
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each block, they were then randomly assigned to one of four
groups: aripiprazole 3 mg/kg (ARI 3, n=9), aripiprazole 10 mg/
kg (ARI 10, n=9), aripiprazole 30 mg/kg (ARI 30, n=9) and vehicle (VEH, n=9), and tested daily under the CS-only (no shock,
30 trials/session) condition for five consecutive days, following
the same procedure as employed before (Feng et al., 2012, 2013;
Swalve and Li, 2012; Zhang and Li, 2012). On each test day, rats
were first injected with aripiprazole or vehicle (mixed doubledistilled water solution containing 30% (v/v) dimethylformamide
and 2% (v/v) glacial acetic acid), 60 min later, they were placed
in the CAR boxes and tested.
Phase 2: Aripiprazole challenge test. One day after the last (5th)
aripiprazole test day, all rats were retrained drug-free for one
session under the CS-only (no shock) condition, followed by another session under the CS-US condition to bring their avoidance responses back to the pre-drug level. These two retraining sessions also ensured that all groups had a comparable level
of avoidance responding before the aripiprazole challenge test,
which occurred one day after the 2nd retraining session. On the
challenge day, all rats were injected with aripiprazole at 1.5 mg/
kg and tested for avoidance performance in the CS-only condition (30 trials) 60 min later.
Phase 3: quinpirole-induced hyperlocomotion test. Two days after
the aripiprazole challenge test in CAR, all rats were first habituated to the locomotor activity apparatus for two days (30 min/
day), with the second day preceded by saline injection prior to
putting them into the test chambers. One day later, they were
injected with quinpirole (1.0 mg/kg, sc) and immediately placed
in the test apparatus for 120 min. Locomotor activity (number of
photobeam breaks) was measured in 10-minute blocks throughout the entire 120-minute test period.

Experiment 2: Effect of repeated aripiprazole
treatment on the PCP-induced hyperlocomotion

This experiment examined how repeated aripiprazole (3.0, 10.0,
30.0 mg/kg, sc) treatment affects the PCP-induced hyperlocomotion. It was designed to examine the generalizability of aripiprazole sensitization across different tests of antipsychotic activity. The entire experiment was comprised of the following three
phases: Phase 1: five days of repeated aripiprazole testing; phase
2: aripiprazole challenge test; and phase 3: quinpirole-induced hyperlocomotion test. Figure 1 summarizes the entire experimental procedure and groups at different phases of the experiment.
Phase 1: Five days of repeated aripiprazole testing. Thirtytwo
rats were randomly assigned to one of five groups: VEH+VEH
(vehicle+saline, n=6), VEH+PCP (vehicle + PCP 3.20 mg/kg,
n=6); ARI 3.0+PCP (ARI 3.0 mg/kg + PCP 3.20 mg/kg, n=6), ARI
10.0+PCP (ARI 10.0 mg/kg + PCP 3.20 mg/kg, n=7) and ARI
30.0+PCP (ARI 30.0 mg/kg + PCP 3.20 mg/kg, n=7). All rats were
first handled and habituated to the locomotor activity apparatus for two days (30 min/day). On each of the next five consecutive days, they were first injected with vehicle (30% (v/v) dimethylformamide and 2% (v/v) glacial acetic acid in water), ARI
3.0, 10.0, 30.0 mg/kg and then immediately placed in the boxes
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for 30 min. At the end of the 30-minute period, they were taken
out and injected with vehicle (saline) or PCP (3.20 mg/kg, sc) and
placed back in the boxes for another 60 min. Locomotor activity
(number of photobeam breaks) was measured in 5 min intervals
throughout the entire 90-minute testing session.
Phase 2: Aripiprazole challenge test. Two days after the last (5th)
ARI test, all rats were returned to the locomotor activity boxes for
one re-habituation session (30 min), followed by the aripiprazole
challenge test one day later. On the challenge day, all rats were
first injected with aripiprazole 3.0 mg/kg and then immediately
placed in the locomotor activity boxes for 30 min. At the end of
the 30-minute period, they were taken out and injected with PCP
(3.20 mg/kg) and placed back in the boxes for another 60 min.
Phase 3: quinpirole-induced hyperlocomotion test. Two days after
the aripiprazole challenge test in CAR, all rats were first habituated
to the locomotor activity apparatus for two days (30 min/day),
with the second day preceded by saline injections prior to habituation. One day later, they were injected with quinpirole (1.0 mg/
kg, sc) and immediately placed in the test apparatus for 120 min.
Locomotor activity (number of photobeam breaks) was measured
in 10-minute blocks throughout the entire 120-minute test period.

Statistical analysis

All data were expressed as mean + standard error of the mean
(SEM). Data from the five drug test sessions (e.g. avoidance response and PCP-induced hyperlocomotion) were analyzed using
a factorial repeated measures analysis of variance (ANOVA) with
the between-subjects factor being drug group and the withinsubjects factor being test session, followed by posthoc least significant difference (LSD) tests. Differences between groups on
the specific drug test days, on the habituation day and on the
challenge tests were analyzed using one-way ANOVAs, followed
by post-hoc LSD tests. Differences between groups on the specific drug test days and on the challenge tests were analyzed
using one-way ANOVAs, followed by post-hoc LSD tests. For all
analyses, p≤0.05 was considered statistically significant and all
data were analyzed using SPSS version 22.

Results
Experiment 1: Effect of repeated aripiprazole
treatment on avoidance response

Phase 1: Five days of repeated aripiprazole testing. Figure 2(a)
shows the mean number of avoidance responses made by rats
in the four groups on the last training (predrug) day and five
drug test days. There was no group difference on the last training day (predrug) (F(3, 32)=0.141, p=0.935). Throughout the
five drug test days, aripiprazole increased its suppression of
avoidance response progressively but not dose-dependently.
Repeated measures ANOVA revealed a main effect of group
(F(3,32)=159.834, p<0.001), day (F(4,128)=13.539, p<0.001), and
a significant group×day interaction (F(12,128)=2.797, p=0.002).
Post-hoc LSD tests show that all three ARI groups made significantly fewer avoidance responses than the VEH group (all

394

J. G a o , R . Q i n , & M . L i i n J o u r n a l o f P s y c h o p h a r m a c o l o g y 2 9 ( 2 0 1 5 )

Figure 2. Repeated aripiprazole treatment increased avoidance response disruption and sensitivity to aripiprazole re-exposure. Number of avoidance responses made by the rats from the three aripiprazole treatment groups (ARI 3.0, 10.0, and 30.0 mg/kg) and the vehicle group (VEH) on the
last training (predrug) day and throughout the five drug test days (a), and on the aripiprazole (1.5 mg/kg) challenge test (b) are expressed as mean
+ standard error of the mean (SEM). *p<0.05, **p<0.01, ***p<0.001 relative to VEH group; #p<0.05 for comparison to the ARI 3.0 group.

ps<0.001), but the three ARI groups did not differ from each
other (all ps>0.283). One-way ANOVA on each test day revealed
that all three ARI groups had significantly lower avoidance than
the VEH group on all five days (all ps<0.001). Additionally, on
day 1, the ARI 30.0 group showed lower avoidance than the ARI
3.0 group (p=0.002).
Phase 2: Aripiprazole challenge test. Figure 2(b) shows the number of avoidance responses on the retraining day (predrug day)
and the aripiprazole challenge day. No significant group difference was detected on the predrug day (F(3,32)=0.913, p=0.446).
However, on the challenge day when all rats were injected with
aripiprazole 1.5 mg/kg, the three ARI (3.0, 10.0, and 30.0 mg/kg)
groups made fewer avoidance responses than the VEH group,
indicating a sensitization effect. One-way ANOVA confirmed a
main effect of group (F(3,32)=4.276, p=0.012). Post-hoc LSD tests
showed that all three ARI groups were significantly different from
the VEH group (p=0.004, 0.018, and 0.005 for ARI 3.0, 10.0, and
30.0), although the three ARI groups did not differ significantly
from each other (all ps>0.559).
Phase 3: Quinpirole-induced hyperlocomotion test. To test
whether the D2/3 receptor system was involved in aripiprazole
sensitization, we tested quinpirole-induced locomotor activity in
rats that were pretreated with ARI (three ARI groups) or vehicle.
This test was conducted two days after the aripiprazole challenge
test. As shown in Figure 3(a), quinpirole at 1.0 mg/kg increased
motor activity during the 120-minute test period, with a higher
motor activity found in the aripiprazole pretreated rats than the
VEH pretreated ones. Repeated measures ANOVA revealed a significant main effect of group (F(3,32)=5.134, p=0.005), timeblock
(F(11,352)=127.823, p<0.001), and a significant group×block interaction (F(33,352)=3.169, p<0.001). Post-hoc LSD tests show

that the ARI 10.0 and ARI 30.0 groups made significantly more
activity than the VEH (ps<0.020) and ARI 3.0 groups (ps<0.008);
but the ARI 3.0 and VEH groups did not differ significantly from
each other (p=0.659). One-way ANOVA with post-hoc LSD
tests revealed that the ARI 10.0 group on the last six 10-minute
blocks (70–120 min, all ps<0.037), and ARI 30.0 group on 2nd–
9th 10-minute blocks (20–90 min, all ps<0.039) had significantly
higher motor activity than the VEH group, while ARI 10.0 group
on the last eight 10-min blocks (50–120 min, all ps<0.040) and
ARI 30.0 group on 2nd–9th 10-minute blocks (20–90 min, all
ps<0.016) had significantly higher motor activity than the ARI
3.0 group.
Similarly, there was also a main effect of group on the total
motor activity in 120 min (Figure 3(b), F(3,32)=5.134, p=0.005)).
Post-hoc LSD tests showed that the ARI 10.0 and ARI 30.0
groups had significantly higher motor activity than the VEH
group (p=0.019 and 0.014, respectively), and the ARI 3.0 group
(p=0.007 and 0.005, respectively). These findings suggest that
repeated aripiprazole treatment induced an increase in D2/3 receptor- mediated function dose-dependently, which may serve
as one mechanism for aripiprazole sensitization in CAR.

Experiment 2: Effect of repeated aripiprazole
treatment on PCP-induced hyperlocomotion

Phase 1: Five days of repeated aripiprazole testing. Figure 4(a)
shows the mean motor activity of the four groups of rats during the 30-min period before PCP or vehicle injection throughout the 5 days of drug testing. Repeated measures ANOVA revealed a main effect of group (F(4,27)=18.538, p<0.001), day
(F(4,108)=47.761, p<0.001), and significant group×day interaction (F(16,108)=6.973, p<0.001). Post-hoc LSD tests revealed that
the four PCP-treated groups had significantly lower motor activity than the VEH+VEH group (all ps≤0.001), mainly on Days 2–5.

Aripiprazole behavioral tests and dopamine D2 receptor function
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Figure 3. Quinpirole-induced locomotor activity in 12 10-minute blocks (a) or in 120 min (b) in the quinpirole-induced hyperlocomotion test. The
test was conducted two days after the last aripiprazole (ARI) challenge test. All rats were injected with quinpirole (1.0 mg/kg, subcutaneously (sc)) and
then measured for motor activity for 120 min. All data are expressed as mean + standard error of the mean (SEM) in 12 10-minute blocks. *p<0.05,
**p<0.01 for comparison to the vehicle (VEH) group; #p<0.05, ##p<0.01 for comparison to the ARI 3.0 group.

Figure 4. Effect of repeated aripiprazole (ARI 3.0, 10.0 and 30.0 mg/kg) treatment on phencyclidine (PCP)-induced hyperlocomotion across the five
test days (n=6–7/group). Locomotor activity in the 30 min before vehicle(VEH) or PCP injection (a) and 60 min after PCP injection (b) are expressed
as mean + standard error of the mean (SEM) for each group. **p<0.01, ***p<0.001 relative to the VEH+VEH group; #p<0.05, ##p<0.01, ###p<0.001
relative to the VEH+PCP group.
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Figure 5. Locomotor activity during the 30-minute test period on the rehabituation day (a), 30-minute test period before phencyclidine (PCP) injection (b) and the 60-minute test period after PCP injection (c) on the aripiprazole (ARI) challenge test day. *p<0.05, **p<0.01, ***p<0.001 relative to the
vehicle (VEH)+VEH group; #p<0.05, ##p<0.01, ###p<0.001 relative to the VEH+PCP group; #p<0.05, ###p<0.001 relative to the ARI 3.0+PCP group.

Figure 4(b) shows the mean motor activity of the five groups
of rats during the 60-minute period after PCP or vehicle injection throughout the five days of drug testing. Two-way repeated
measures ANOVA revealed a significant main effect of group
(F(4,27)=20.641, p<0.001), day (F(4,108)=4.214, p=0.003), and
a significant group×day interaction (F(16,108)=6.786, p<0.001).
Post-hoc LSD tests revealed that the three ARI+PCP (ARI 3.0,
10.0, and 30.0 +PCP) groups exhibited significantly lower motor activity compared to the VEH+PCP group (all ps<0.001). The
VEH+PCP group had significantly higher motor activity than the
VEH+VEH group (p<0.001), indicating a strong psychomotor activation effect of this dose of PCP. One-way ANOVA on each
test day revealed that the all three ARI (3.0, 10.0 and 30.0+PCP)
groups had significantly lower activity than the VEH+PCP group
on Days 2–5 (all ps<0.016). In addition, the ARI 10.0+PCP group
also had significantly lower motor activity than VEH+PCP group
(p=0.002) and ARI 3.0+PCP group (p=0.004) on Day 1.
Phase 2: Re-habituation and aripiprazole challenge test. On the
re-habituation day, rats previously treated with VEH+PCP or
ARI 30.0+PCP had lower motor activity than other groups (Figure 5(a)). One-way ANOVA showed a significant effect of group
(F(4,27)=6.870, p=0.001). Post-hoc test showed that the two
ARI (3.0 and 10.0 mg/kg) groups (all ps<0.041) and VEH+VEH
group (p=0.003) had significantly higher motor activity than the
VEH+PCP group, and the ARI 3.0+PCP group had higher motor activity than the ARI 10.0+PCP (p=0.039) and ARI 30.0+PCP
groups (p<0.001). In addition, the ARI 30.0+PCP group showed
significantly lower motor activity relative to the VEH+VEH group
(p=0.004). These results suggest that concurrent 3.0 and 10.0
mg/kg ARI treatment with PCP prevented the PCP-withdrawalinduced decrease in spontaneous motor activity.

On the ARI sensitization challenge test, in the first 30 min
(Figure 5(b)), the three ARI groups had lower motor activity
than the vehicle group. One-way ANOVA revealed a main effect of group (F(4,27)=4.024, p=0.011). The ARI 10.0+PCP group
had significantly lower motor activity than the VEH+PCP group
(p=0.011), and both ARI 10.0+PCP and ARI 30.0+PCP groups
had significantly lower motor activity than the VEH+VEH group
(p=0.001, 0.015, respectively). In the 60-minute test period after
PCP injection (Figure 5(c)), one-way ANOVA revealed a main effect of group (F(4,27)=7.678, p<0.001). Post hoc comparisons revealed that the all three ARI (ARI 3.0, 10.0 and 30.0+PCP) groups
had significantly lower motor activity than the VEH+PCP group
(all ps≤0.003), indicating a ARI sensitization effect.
Collectively, results from this experiment provided further evidence of aripiprazole sensitization. Similar to aripiprazole sensitization observed in the conditioned avoidance test (experiment
1), this effect was manifested as an enhanced inhibition of PCPinduced hyperlocomotion (an index of antipsychotic activity) in
the ARI treated animals.
Phase 3: Quinpirole-induced hyperlocomotion test. To test
whether the D2/3 receptor system was involved in aripiprazole
sensitization, we tested quinpirole-induced locomotor activity in rats tested in the PCP model. This test was conducted
two days after the ARI challenge test in PCP model. As shown
in Figure 6(a), quinpirole at 1.0 mg/kg increased motor activity
during the 120-minute test period, with a higher motor activity
found in the ARI 30.0+PCP pretreated rats than the VEH+PCP
pretreated ones. Repeated measures ANOVA revealed a significant main effect of group (F(4,27)=3.794, p=0.014), time-block
(F(11,297)=43.61, p<0.001), and a significant group×block interaction (F(44,297)=1.926, p=0.001). Post-hoc LSD tests show that
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Figure 6. Quinpirole-induced locomotor activity in 12 10-min blocks (a) or in 120 min (b) in the quinpirole-induced hyperlocomotion test. The test
was conducted two days after the last aripiprazole (ARI) challenge test. All rats were injected with quinpirole (1.0 mg/kg, subcutaneously (sc)) and
then measured for motor activity for 120 min. All data are expressed as mean + standard error of the mean (SEM) in 12 10-minute blocks. PCP: phencyclidine; VEH: vehicle. *p<0.05, **p<0.01, ***p<0.001 for comparison to the VEH+VEH group; #p<0.05, ##p<0.01 for comparison to the VEH+PCP
group; $p<0.05, $$p<0.01 for comparison to the ARI 3.0+PCP group; &p=0.05 for comparison to the ARI 10.0+PCP group.

the ARI 30.0+PCP group was significantly more active than the
VEH+VEH group (p=0.002), the VEH+PCP group (p=0.014), and
the ARI 3.0+PCP group (p=0.005); but the ARI 3.0+PCP and ARI
10.0+PCP groups did not differ significantly from the VEH+PCP
group (all ps>0.524). One-way ANOVA with post-hoc LSD tests
revealed that the ARI 30.0+PCP group had significantly higher
motor activity than the VEH+PCP group on the 3rd–9th 10-minute blocks (30–90 min, all ps<0.039), VEH+VEH group on all 12
10-minute blocks (all ps<0.035), and ARI 3.0+PCP group at 10,
40–120 min points (ps<0.043), and ARI 10.0+PCP group at the
10 and 60 min points (ps<0.015), while the ARI 10.0 group had
significantly higher motor activity than the ARI 3.0 group at the
90 and 110 min points (all ps<0.049).
Similarly, the group difference on the total motor activity in
120 min was also significant (Figure 6(b), F(4,27)=3.794, p=0.014).
Post-hoc LSD tests showed that the ARI 30.0+PCP group was
significantly different from the VEH+VEH group (p=0.002),
VEH+PCP group (p=0.014), ARI 3.0+PCP group (p=0.005), and
ARI 10.0+PCP group (p=0.050). These data are consistent with
those reported in experiment 1 and suggest that repeated aripiprazole treatment induced an increase in D2/3 receptor-mediated function dose-dependently, a change that may partially underlie aripiprazole sensitization.

Discussion
Aripiprazole is an atypical antipsychotic drug with mechanisms
of action distinctive from the more widely used atypicals, such
as clozapine, risperidone, olanzapine, and quetiapine. Aripiprazole shows high affinity for dopamine D2 receptors but as a partial agonist rather than a full antagonist at these receptors (Aihara et al., 2004; Burris et al., 2002; Kikuchi et al., 1995; Lawler
et al., 1999; Shapiro et al., 2003). As a result, it acts as a D2 receptor agonist at receptor sites where dopaminergic transmis-

sion is significantly decreased while acting as an antagonist at
other dopaminergic sites with normal or increased transmission,
functioning as a dopamine activity stabilizer. In addition to the
action of aripiprazole on dopamine receptors, this drug shows
partial agonism at 5-HT1A receptors and antagonism at 5-HT2A
receptors (Jordan et al., 2002; Kikuchi et al., 1995). In the present study, we demonstrated that repeated aripiprazole treatment
for five days caused an augmentation of its disruption of avoidance responding and inhibition of PCP-induced hyperlocomotion in a dose-dependent fashion. This effect was observed in
both the induction phase and expression phase using two measures of sensitization (withinsubjects and between-subjects comparisons). Therefore, despite its novel mechanisms, aripiprazole
induced a sensitized behavioral effect similar to those of other
atypicals (e.g. olanzapine, risperidone, and asenapine). Furthermore, repeated aripiprazole treatment also increased sensitivity
to quinpirole challenge, indicating an upregulation of D2/3-mediated neurotransmission. These findings reveal that aripiprazole
shares a similar feature of sensitization with haloperidol, asenapine, olanzapine, and risperidone in behavioral tests of antipsychotic activity, and that this long-term effect is likely related
to plastic changes in D2/3-receptors and other receptors that aripiprazole targets.
Previous work has shown that acute aripiprazole treatment
at 10 and 30 mg/kg significantly suppresses conditioned avoidance response in rats (Hertel et al., 2005; Natesan et al., 2006).
The present study extended this finding to show that repeated
aripiprazole treatment intensifies this suppression over time and
this intensification was long-lasting and could be detected in a
later drug challenge test, as rats previously treated with aripiprazole showed significantly lower avoidance than the drug-naive rats. Similarly in the PCP-induced hyperlocomotion test, our
finding on the acute aripiprazole effect is consistent with a previous report showing that aripiprazole reduces PCP-induced in-
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crease in locomotor activity at 1–30 mg/kg (Nordquist et al.,
2008). Again, the novel finding is on the sensitization effect of
aripiprazole that manifested as the progressively enhanced suppression of PCP-induced hyperlocomotion during the induction
phase (Figure 4(b)), and an enhanced sensitivity to aripiprazole
challenge in the expression phase (Figure 5(b) and (c)). To our
knowledge, this is the first report on the repeated behavioral effects of aripiprazole in these two models. The fact that the same
sensitization effect was found in two distinct behavioral assessments supports the generalizability of such an effect. Because
aripiprazole at the doses used here induces approximately 65–
85% D2 occupancies in rodents (Natesan et al., 2006), a level
which is commonly found in human volunteers treated with adequate doses of aripiprazole (Yokoi et al., 2002). Thus, it seems
likely that the doses we used were sufficient and clinically relevant, and the sensitization effect of aripiprazole may reflect an
intrinsic feature of this drug.
This intrinsic feature does not distinguish aripiprazole from
other atypical antipsychotic drugs at least at the behavioral level
since most other antipsychotic drugs, except for clozapine, also
induce a sensitization effect in these two widely used behavioral
tests (Feng et al., 2013; Li et al., 2012; Mead and Li, 2010; Qiao
et al., 2013; Qin et al., 2013; Swalve and Li, 2012; Zhang and Li,
2012). Clozapine is the only drug that induces a tolerance effect in these tests (Feng et al., 2013; Li et al., 2010, 2012). On
this front, it can be inferred that aripiprazole has a clinical profile similar to that of olanzapine, risperidone, and asenapine but
different from that of clozapine. As a basic principle in psychopharmacology, the demonstration of aripiprazole sensitization
further supports the notion that once an organism is exposed
to an antipsychotic drug, this drug experience stays with it for
a long period of time and may have a drug memory-like characteristic. Clinically, antipsychotic sensitization has been considered as a behavioral mechanism underlying the therapeutic effects of antipsychotic treatment (Kapur et al., 2006; Sun et al.,
2009), as it matches with the early onset and progressive improvement pattern of antipsychotic response in patients (Agid
et al., 2003). Thus, it can be said that the gradual improvement
of psychotic symptoms over time is due to the drug-induced
sensitization process that intensifies the behavioral effects of
the drug. However, antipsychotic sensitization may also underlie the drug-induced extrapyramidal motor syndrome and tardive dyskinesia (Turrone et al., 2005), an idea also supported by
the findings that acute or repeated administration of many antipsychotic drugs, including aripiprazole, causes an impairment
of motor function or coordination (Barnes et al., 1990; Burda et
al., 2011; Nordquist et al., 2008). At this point, the clinical significance of antipsychotic sensitization in general and aripiprazole
sensitization in particular is still not clear. From this perspective,
understanding the clinical significance of aripiprazole sensitization and associated neurobiological mechanisms may help enhance our understanding of the behavioral and neurobiological
mechanisms of clinical antipsychotic response.
One interesting finding is that the VEH+PCP group had significantly lower spontaneous motor activity than the VEH+VEH
group on the rehabituation day when all rats were placed in the
test boxes drug-free for 30 min (Figure 5(a)), suggesting a PCP

withdrawal-induced decrease in motor activity. This effect has
not been reported before (Qin et al., 2013) and may reflect PCP
withdrawal- induced anxiety or depression which is well known
in the literature (Audet et al., 2007; Baird et al., 2008; Noda et
al., 1995; Renoir et al., 2012; Spielewoy and Markou, 2003). Interestingly, concurrent ARI treatment at 3 and 10 mg/kg alleviated this effect. Similar findings have been reported with clozapine and risperidone (Grayson et al., 2007; Qiao et al., 2001).
ARI at 30 mg/kg did not exhibit this effect, possibly due to the
qualitative and quantitative differences in brain plasticity between this dose of ARI and other doses. For example, Peselmann
et al. (2013) found that the gene expression of gamma-aminobutyric acid (GABA) transmembrane transporters Slc6a1 (Gat1)
and Slc6a11 (Gat3) in the hippocampus, caudate nucleus and putamen, and cerebral cortex were increased by a lower dose (10
mg/kg) rather than a higher dose (40 mg/kg) of ARI (Peselmann
et al., 2013), and Zocchi et al. (2005) demonstrated that aripiprazole at lower dose (0.3 mg/ kg) but not higher doses (3 and
30 mg/kg) produced a significant increase in extracellular levels
of dopamine in the mouse frontal cortex. Future studies should
attempt to replicate this effect and the effect of PCP withdrawalinduced decrease in motor activity to further understand their
neurobiological mechanisms.
At the receptor level, aripiprazole-induced sensitization
seems partially to be accompanied by drug-induced functional
changes in dopamine D2/3 receptors. This was revealed in the
quinpirole-induced hyperlocomotion test, a validated behavioral assay of D2-mediated neurotransmission. Aripiprazole-pretreated rats had significantly higher motor activity than the corresponding vehicle rats under the quinpirole challenge. Seeman
(2008) also found that one week of aripiprazole treatment significantly increased the ratio of D2High receptors in the striatum of
adult rats, an effect that is often associated with dopamine supersensitivity (Seeman et al., 2005). Our current finding is similar
to our previously reported risperidone-induced sensitization, as
risperidonepretreated rats were also more active than the corresponding vehicle rats when challenged with quinpirole (Gao
and Li, 2013). In addition to dopamine D2/3 receptors, serotonin
5-HT2A/2C receptor systems may also play important roles in antipsychotic sensitization. Recently, we showed that pretreatment
of quinpirole or 2,5-dimethoxy-4-iodo-amphetamine (DOI, a selective 5-HT2A/2C agonist) attenuated the magnitude of olanzapine sensitization effect (Li et al., 2010). In the case of aripiprazole
sensitization, the neuroreceptor mechanisms may involve other
receptors in addition to dopamine D2/3. First, aripiprazole has
additional high affinity for several 5-HT receptors (e.g. 5-HT1A,
5-HT2A, 5-HT2B and 5-HT7), α1-adrenergic and H1-histamine receptors, and functions as an inverse agonist at 5-HT2B receptors and a partial agonist at 5-HT2A, 5-HT2C, D3, and D4 receptors
(Shapiro et al., 2003). It is conceivable that five days of repeated
aripiprazole treatment could also have altered the functions of
these receptors in addition to alteration of D2 receptors. Second,
Inoue et al. (1997) showed that repeated administration of aripiprazole at 12–100 mg/kg dose range for three weeks did not
induce any up-regulation of dopamine D2 mRNA expression in
the striatum. Tadokoro et al. (2012) reported that aripiprazole at
1.5 mg/kg/day via minipump for 14 days does not cause an in-
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crease in D2 binding sites and dopamine supersensitivity in adult
rats. These findings suggest that D2 receptor-mediated neurotransmission might not be critical in support of aripiprazole’s
long-term effect. We speculate that the observed enhanced sensitivity to quinpirole challenge in aripiprazole-treated rats may
reflect drug-induced changes on other receptors (e.g. 5-HT1A,
5-HT2A, 5-HT2B) in other parts of the brain (e.g. medial prefrontal cortex). Finally, aripiprazole at 3.0 mg/kg did not induce any
changes in quinpirole-induced hyperlocomotion in motor activity in both experiments (Figure 3(b) and Figure 6(b)): however,
it clearly induced a sensitization effect (Figure 2(b) and Figure
5(c)), suggesting that dopamine D2/3 might be just one of many
mechanisms involved in aripiprazole sensitization.
In summary, aripiprazole is a novel antipsychotic drug which
shares a similar repeated behavioral profile with most antipsychotic drugs (e.g. olanzapine, risperidone, asenapine) on the basis of the findings that its repeated treatment caused a sensitization effect in both the induction and expression phases of
the CAR and PCPinduced hyperlocomotion tests. One potential receptor mechanism responsible for its sensitization effect
is the functional changes in dopamine D2/3 system. Future work
should explore other molecular mechanisms and identify the relevant neurochemical systems and various forms of neuroplasticity (Allen et al., 2011; Konradi and Heckers, 2001; Lieberman et
al., 2008; Meltzer et al., 1989).
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